PL1874748T3 - 2-Aminokarbonylo-podstawione związki piperazynowe lub diazacykliczne jako modulatory inhibitorów białek apoptozy (IAP) - Google Patents

2-Aminokarbonylo-podstawione związki piperazynowe lub diazacykliczne jako modulatory inhibitorów białek apoptozy (IAP)

Info

Publication number
PL1874748T3
PL1874748T3 PL06769822T PL06769822T PL1874748T3 PL 1874748 T3 PL1874748 T3 PL 1874748T3 PL 06769822 T PL06769822 T PL 06769822T PL 06769822 T PL06769822 T PL 06769822T PL 1874748 T3 PL1874748 T3 PL 1874748T3
Authority
PL
Poland
Prior art keywords
iap
diaza
modulators
cyclic compounds
protein inhibitor
Prior art date
Application number
PL06769822T
Other languages
English (en)
Inventor
Robert Eckl
Roswitha Taube
Michael Almstetter
Michael Thormann
Andreas Treml
Christopher Straub
Zhuoliang Chen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1874748T3 publication Critical patent/PL1874748T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL06769822T 2005-04-13 2006-04-13 2-Aminokarbonylo-podstawione związki piperazynowe lub diazacykliczne jako modulatory inhibitorów białek apoptozy (IAP) PL1874748T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005017116A DE102005017116A1 (de) 2005-04-13 2005-04-13 Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
EP06769822A EP1874748B1 (en) 2005-04-13 2006-04-13 2 -aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators
PCT/US2006/013943 WO2006113376A1 (en) 2005-04-13 2006-04-13 2 -aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators

Publications (1)

Publication Number Publication Date
PL1874748T3 true PL1874748T3 (pl) 2010-01-29

Family

ID=36829712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06769822T PL1874748T3 (pl) 2005-04-13 2006-04-13 2-Aminokarbonylo-podstawione związki piperazynowe lub diazacykliczne jako modulatory inhibitorów białek apoptozy (IAP)

Country Status (16)

Country Link
US (2) US7932255B2 (pl)
EP (1) EP1874748B1 (pl)
JP (1) JP2008536861A (pl)
KR (1) KR20070119088A (pl)
CN (1) CN101160297B (pl)
AT (1) ATE439355T1 (pl)
AU (1) AU2006236714A1 (pl)
BR (1) BRPI0608783A2 (pl)
CA (1) CA2604821A1 (pl)
DE (2) DE102005017116A1 (pl)
ES (1) ES2328405T3 (pl)
MX (1) MX2007012703A (pl)
PL (1) PL1874748T3 (pl)
PT (1) PT1874748E (pl)
RU (1) RU2007141578A (pl)
WO (1) WO2006113376A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
RU2418807C2 (ru) 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
AR077688A1 (es) 2009-08-04 2011-09-14 Takeda Pharmaceutical Compuestos heterociclicos, utiles en el tratamiento de cancer
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
JP5760078B2 (ja) * 2011-03-16 2015-08-05 田辺三菱製薬株式会社 含窒素飽和複素環化合物
US10875851B2 (en) 2016-11-18 2020-12-29 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
CN107879997B (zh) * 2017-12-25 2021-01-26 三峡大学 一种小分子抑制剂sld1338及其在制药中的应用
CN112533898A (zh) * 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
US20250282760A1 (en) * 2022-05-06 2025-09-11 Merck Sharp & Dohme Llc Orexin receptor agonists
WO2024107615A1 (en) * 2022-11-17 2024-05-23 Merck Sharp & Dohme Llc Orexin receptor agonists
WO2025090605A1 (en) * 2023-10-24 2025-05-01 University Of Houston System Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
CA2324226C (en) * 1998-03-19 2012-06-05 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
JP2002533455A (ja) * 1998-12-23 2002-10-08 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの新規なインヒビター
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
CN100384819C (zh) * 2002-07-02 2008-04-30 诺瓦提斯公司 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂

Also Published As

Publication number Publication date
MX2007012703A (es) 2008-01-14
AU2006236714A1 (en) 2006-10-26
DE102005017116A1 (de) 2006-10-26
US20080207630A1 (en) 2008-08-28
RU2007141578A (ru) 2009-05-20
WO2006113376A1 (en) 2006-10-26
EP1874748B1 (en) 2009-08-12
ATE439355T1 (de) 2009-08-15
BRPI0608783A2 (pt) 2010-01-26
EP1874748A1 (en) 2008-01-09
JP2008536861A (ja) 2008-09-11
CA2604821A1 (en) 2006-10-26
ES2328405T3 (es) 2009-11-12
US20110183955A1 (en) 2011-07-28
KR20070119088A (ko) 2007-12-18
DE602006008447D1 (de) 2009-09-24
PT1874748E (pt) 2009-10-28
US7932255B2 (en) 2011-04-26
CN101160297B (zh) 2011-07-27
CN101160297A (zh) 2008-04-09

Similar Documents

Publication Publication Date Title
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
PT1874748E (pt) Compostos piperazina ou diaza-cíclicos substituídos com 2-aminocarbonilo moduladores do inibidor da proteína da apoptose (iap)
WO2008014238A3 (en) Dimeric iap inhibitors
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
CR7056A (es) Derivados de 3-(4-amidopirrol-2-ilmetilden)-2-indolinona como inhibidores de la protein quinasa
MX2010006203A (es) Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
MY146548A (en) Certain chemicals entities, compositions, and methods
MX2009004714A (es) Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa.
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
WO2008014229A3 (en) Dimeric iap inhibitors
WO2007090881A3 (en) Modified release formulation
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
WO2006034391A3 (en) Indole inhibitors of 15-lipoxygenase
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof
UA96742C2 (en) Mek inhibitors and use thereof
EA201990219A3 (ru) Ингибиторы mek и способы их применения
HK1190405A1 (zh) 作为丙酮酸激酶m2(pmk2)调节物的新颖的n-(4-(氮杂环丁烷-1-羰基)苯基)-(异型)芳基磺胺衍生物